Compare Abeona Therapeutics Inc (ABEO) vs Tidewater Inc (TDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tidewater Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Tidewater Inc trades at $73.24 (market cap $3.54B). The key difference: Tidewater Inc is far larger — about 9.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TDW | |
|---|---|---|
Market Cap | $373.32M | $3.54B |
Sector | Health | Utilities |
52-Week High | $7.23 | $91.12 |
52-Week Low | $4.17 | $46.32 |
Enterprise Value | $228.22M | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Tidewater (TDW) trades at $68.19, up 0.1% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. Recent earnings misses in Q1 2026 and Q4 2025 contrast with strong 2025 profitability, including a 22.16% net income margin and 24.03% ROE. The company reported $1.35B revenue in 2025, with net income of $334.66M, though 2026 projections indicate a slight decline. Positive cash flow from operations of $379.11M in 2025 supports financial health, while analyst sentiment remains cautious with a 'Hold' consensus.
Outlook: TDW's valuation appears reasonable with a P/E of 11.5 and EV/EBITDA of 8.52, but recent earnings volatility and a 61.54% analyst hold rating suggest near-term headwinds. Key risks include execution challenges amid declining revenue projections and competitive pressures in offshore marine services. Upside potential hinges on improved earnings consistency and sector recovery, while downside risks involve further profit margin compression and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
